Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.

Journal: The Lancet. Global health

Volume: 11

Issue: 10

Year of Publication: 2023

Affiliated Institutions:  Institute for Global Health, University College London, London, UK. Electronic address: andrew.phillips@ucl.ac.uk. Institute for Global Health, University College London, London, UK. Institute for Global Health, University College London, London, UK; Africa Health Research Institute, KwaZulu-Natal, South Africa. London School of Hygiene & Tropical Medicine, London, UK. Centre for Health Economics, University of York, York, UK. CeSHHAR Zimbabwe, Harare, Zimbabwe; Liverpool School of Tropical Medicine, Liverpool, UK. Bill & Melinda Gates Foundation, Seattle, WA, USA. AfroCAB, Lusaka, Zambia. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. University of Queensland, Brisbane, QLD, Australia. Office of the Global AIDS Coordinator, Department of State, Washington, DC, USA.

Abstract summary 

Post-exposure prophylaxis (PEP) offers protection from HIV after condomless sex, but is not widely available in a timely manner in east, central, southern, and west Africa. To inform the potential pilot implementation of such an approach, we modelled the effect and cost-effectiveness of making PEP consisting of tenofovir, lamivudine, and dolutegravir (TLD) freely and locally available in communities without prescription, with the aim of enabling PEP use within 24 h of condomless sex. Free community availability of TLD (referred to as community TLD) might also result in some use of TLD as pre-exposure prophylaxis (PrEP) and as antiretroviral therapy for people living with HIV.Using an existing individual-based model (HIV Synthesis), we explicitly modelled the potential positive and negative effects of community TLD. Through the sampling of parameter values we created 1000 setting-scenarios, reflecting the uncertainty in assumptions and a range of settings similar to those seen in east, central, southern, and west Africa (with a median HIV prevalence of 14·8% in women and 8·1% in men). For each setting scenario, we considered the effects of community TLD. TLD PEP was assumed to have at least 90% efficacy in preventing HIV infection after condomless sex with a person living with HIV.The modelled effects of community TLD availability based on an assumed high uptake of TLD resulted in a mean reduction in incidence of 31% (90% range over setting scenarios, 6% increase to 57% decrease) over 20 years, with an HIV incidence reduction over 50 years in 91% of the 1000 setting scenarios, deaths averted in 55% of scenarios, reduction in costs in 92% of scenarios, and disability-adjusted life-years averted in 64% of scenarios with community TLD. Community TLD was cost-effective in 90% of setting scenarios and cost-saving (with disability-adjusted life-years averted) in 58% of scenarios. When only examining setting scenarios in which there was lower uptake of community TLD, community TLD is cost-effective in 92% of setting scenarios.The introduction of community TLD, enabling greater PEP access, is a promising approach to consider further in pilot implementation projects.Bill & Melinda Gates Foundation to the HIV Modelling Consortium.

Authors & Co-authors:  Phillips Andrew N AN Bansi-Matharu Loveleen L Shahmanesh Maryam M Hargreaves James R JR Smith Jennifer J Revill Paul P Sibanda Euphemia E Ehrenkranz Peter P Sikwese Kenly K Rodger Alison A Lundgren Jens D JD Gilks Charles F CF Godfrey Catherine C Cowan Frances F Cambiano Valentina V

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  15
Identifiers
Doi : 10.1016/S2214-109X(23)00383-2
SSN : 2214-109X
Study Population
Male,Women
Mesh Terms
Male
Other Terms
Study Design
Study Approach
Country of Study
Publication Country
England